Оксана Богдашевская - Энциклопедия женского здоровья. Контрацепция без последствий

20. Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks. Product information updated to help women make informed decisions about their choice of contraception // European Medicines Agency. – 2014. – 4 р.

21. Heit J., et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study //Ann. Intern. Med. – 2005. – Vol. 143 (10). – Р. 697–706.

22. Carrie Armstrong ACOG Guidelines on Noncontraceptive Uses of Hormonal Contraceptives // Am. Fam. Physician. 2010. Aug 1. Vol. 82 (3). P. 288–295.

23. Curtis K.M., Tepper N.K., Jatlaoui T.C. et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. // MMWR Recomm. Rep. 2016. Vol. 65 (3). P.1. [Epub 2016 Jul 29] [PMID 27467196].

24. Calhoun A.H. Hormonal Contraceptives and Migraine With Aura-Is There Still a Risk? // Headache. 2017. Vol. 57 (2). P. 184. [Epub 2016 Oct 24] [PMID 27774589].

25. Chürks M. et al. Migraine and cardiovascular disease: systematic review and meta-analysis // BMJ. 2009. Vol. 339. P. 657–665. [PMID: 19861375].

26. Tepper N.K., Whiteman M.K., Zapata L.B. et al. Safety of hormonal contraceptives among women with migraine: A systematic review. //Contraception. 2016. Vol. 94 (6). P. 630–640. [PMID 27153744].

27. Edlow A.G., Bartz D. Hormonal contraceptive options for women with headache: a review of the evidence. // Rev. Obstet. Gynecol. 2010. Vol. 3 (2). P. 55–65. [PMID: 20842283].

28. Schaffir J, Worly BL, Gur TL. Combined hormonal contraception and its effects on mood: a critical review./Eur J Contracept Reprod Health Care. 2016;21(5):347. Epub 2016 Aug 15.

29. Wiréhn AB, Foldemo A, Josefsson A et al. Use of hormonal contraceptives in relation to antidepressant therapy: A nationwide population-based study./ Eur J Contracept Reprod Health Care. 2010;15(1):41.

30. Skovlund CW, Mørch LS, Kessing LV, LidegaardØ. Association of Hormonal Contraception With Depression./ JAMA Psychiatry. 2016;73(11):1154.

31. Harlow BL, Wise LA, Otto MW et al. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles./ Arch Gen Psychiatry. 2003 Jan;60(1):29–36.

32. Joffe H, Cohen LS, Harlow BL Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration./ Am J Obstet Gynecol. 2003 Dec;189(6):1523-30.

33. Toffol E, Heikinheimo O, Koponen P et al. Hormonal contraception and mental health: results of a population-based study./ Hum Reprod. 2011 Nov;26(11):3085-93. Epub 2011 Aug 12.

34. Keyes KM, Cheslack-Postava K, Westhoff C et al. Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States./ Am J Epidemiol. 2013 Nov;178(9):1378-88. Epub 2013 Sep 15.

35. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression./ JAMA Psychiatry. 2016; 73(11):1154.

36. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Suicide Attempts and Suicides./ Am J Psychiatry. 2018 Apr 1;175(4):336–342. Epub 2017 Nov 17.

37. Lidegaard Ø, Løkkegaard E, Jensen A et al. Thrombotic stroke and myocardial infarction with hormonal contraception./N Engl J Med. 2012 Jun 14;366(24):2257-66.

38. Berlin I, Aubin HJ, Thomas D. Comment on the Association of Hormonal Contraception With Suicide Attempts and Suicides./ Am J Psychiatry. 2018 Jul 1;175(7):683.

39. Heinemann L. A., Thiel C., Assmann A., Möhner S. Frequency and reasons for switching/stopping use of oral contraceptives. Results of the German Cohort Study on Women Health // Zentralbl. Gynakol. 2001. Vol. 123. N 10. P. 568–577.

40. Burrows L.J., Basha M., Goldstein A.T.The effects of hormonal contraceptives on female sexuality: a review. J Sex Med 2012 Sep 12;9 (9):2213–23. Epub 2012 Jul 12.

41. Boozalis A, Tutlam NT, Chrisman Robbins C. Sexual Desire and Hormonal Contraception // Obstet Gynecol. 2016 Mar;127 (3): 563-72.

42. Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review./ Eur J Contracept Reprod Health Care. 2013 Feb;18 (1):27–43.

43. Zethraeus N, Dreber A, Ranehill E. Combined Oral Contraceptives and Sexual Function in Women-a Double-Blind, Randomized, Placebo-Controlled Trial.// J Clin Endocrinol Metab. 2016 Nov;101(11):4046–4053. Epub 2016 Aug 15.

44. Oranratanaphan S, Taneepanichskul S. A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido.// J Med Assoc Thai. 2006;89 Suppl 4:S17.

45. Bancroft J, Davidson DW, Warner P. Androgens and sexual behaviour in women using oral contraceptives.// Clin Endocrinol (Oxf). 1980;12(4):327.

46. Di Carlo С., Gargano V., De Rosa N., Antonio Tommaselli G. A. et al. Effects of estradiol valerate and dienogest on quality of life and sexual function according to age // Gynecol. Endocrinol. 2014. Vol. 30. N 12. P. 925–928.

47. Goldstein I.et al.Hypoactive Sexual Desire Disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) Expert Consensus Panel Review / Mayo Clinic Proceedings, Volume 92, Issue 1, 114–128.

48. Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users oral contraceptives: cohort data from the Royal College of General Practitioners oral contraception study. BMJ 2007; 335: 651.

49. Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers [published online January 18, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2017.4942.

50. Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiology, Biomarkers & Prevention 2013; 22(11):1931–1943.

51. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncology 2015; 16(9):1061–1070.

52. Cullins VE. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate.// J Reprod Med. 1996; 41(5 Suppl):428.

53. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.// J Reprod Med. 1996; 41(5 Suppl):419.

54. Montz FJ, Bristow RE, Bovicelli A. et al. Intrauterine progesterone treatment of early endometrial cancer.// Am J Obstet Gynecol. 2002; 186(4):651.

55. Soini T, Hurskainen R, Grénman S. et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland.// Obstet Gynecol. 2014 Aug;124(2 Pt 1):292-9.

56. Jareid M, Thalabard JC, Aarflot M. et al. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study // Gynecol Oncol. 2018;149(1):127. Epub 2018 Mar 2.

57. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals. Combined estrogen-progestogen contraceptives. Exit Disclaimer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2012; 100A:283–311.

58. Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: An analysis from the Ovarian Cancer Cohort Consortium. Journal of Clinical Oncology 2016; 34(24):2888–2898.

59. Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstetrics and Gynecology 2013; 122(1):139–147.

60. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: The Royal College of General Practitioners’ Oral Contraception Study. American Journal of Obstetrics and Gynecology 2017; 216(6):580.e1-580.e9.

61. Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiology, Biomarkers & Prevention 2013; 22(11):1931–1943.

62. Luan NN, Wu L, Gong TT, et al. Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-analysis of epidemiological studies. Cancer Causes & Control 2015; 26(1):65–78.

63. Murphy N, Xu L, Zervoudakis A, et al. Reproductive and menstrual factors and colorectal cancer incidence in the Women’s Health Initiative Observational Study. British Journal of Cancer 2017; 116(1):117–125.

64. Vicus D, Finch A, Rosen B. et al. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.// Gynecol Oncol. 2010 Aug;118(2):155–9. Epub 2010 May 10.

65. Jordan SJ, Green AC, Whiteman DC et al. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis.// Int J Cancer. 2008;122(7):1598.

66. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347(9017):1713–1727.

67. Beaber EF, Buist DS, Barlow WE, et al. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Research 2014; 74(15):4078–4089.

68. Hankinson SE, Colditz GA, Manson JE et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses’ Health Study, United States).//Cancer Causes Control. 1997; 8(1):65.

69. Vessey M, Painter R Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004.// Br J Cancer. 2006; 95(3):385. Epub 2006 Jul 4.

70. Vessey M, Yeates D Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study // Contraception. 2013 Dec; 88(6):678–83. Epub 2013 Sep 2.

71. Marchbanks PA, McDonald JA, Wilson HG et al. Oral contraceptives and the risk of breast cancer.// N Engl J Med. 2002;346(26):2025.

72. Mørch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. New England Journal of Medicine 2017; 377(23):2228–2239.

73. Moorman PG, Havrilesky LJ, Gierisch JM et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.// J Clin Oncol. 2013 Nov;31(33):4188-98. Epub 2013 Oct 21.

74. Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. European Journal of Cancer 2010; 46(12):2275–2284.

75. McLaughlin JR, Risch HA, Lubinski J. et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.// Lancet Oncol. 2007;8(1):26.

76. Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361(9364):1159–1167.

77. Moreno V, Bosch FX, Muñoz N. et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study.// Lancet. 2002;359(9312):1085.

78. Gierisch JM, Coeytaux RR, Urrutia RP et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review.// Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1931-43. Epub 2013 Sep 6.